bortezomib + ascorbic acid + melphalan

This drug is a **three-drug combination** regimen consisting of **bortezomib**, **ascorbic acid (vitamin C)**, and **melphalan**. It has been studied as a frontline and salvage regimen for **multiple myeloma**, most notably under the acronym **BAM**. - **Bortezomib** is a proteasome inhibitor that induces apoptosis and inhibits proliferation of multiple myeloma cells by blocking the 26S proteasome, leading to dysregulation of protein homeostasis. - **Melphalan** is an alkylating agent that crosslinks DNA and inhibits DNA and RNA synthesis, causing cytotoxicity mostly in rapidly dividing malignant cells. - **Ascorbic acid** (vitamin C) is used in this regimen to reduce glutathione levels, potentially enhancing the cytotoxic effects of both bortezomib and melphalan. Synergistic effects have been reported with this combination, leading to high disease control rates in trials; the regimen is steroid- and immunomodulatory drug (IMiD)-free and has been reported as effective and well tolerated for newly diagnosed and relapsed/refractory multiple myeloma[4][7].

Other names

BAM